
Oxford Genetics boosts cell/gene therapy R&D with new facility
pharmafile | October 20, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Oxford Genetics, expansionÂ
Oxford Genetics has moved its operations to the Medawar centre in the city, upscaling its infrastructure and staff to keep pace with its rapid growth over the past year.
The move is the latest major step in the firm’s growth stratregy in developing and supporting cancer-fighiting technologies. The company specialises in DNA design, protein expression optimisation and cell line development technologies and services, and these new facilities increase its laboratory space to 5,700 square feet and include dedicated cell development suites and new robotic platforms for process automation; this helps to significantly boost the company’s research and development capacity, particularly in the field of cell and gene therapy, a potentially effective, non-harmful treatment for cancer and genetic disorders.
Ryan Cawood (pictured, right), CEO at Oxford Genetics, remarked: ‘As Oxford Genetics continues to grow, it is essential that we build capacity to accommodate our expanding team and suite of technologies and services. The dedicated facilities will enable us to meet more client requests, and allows us to broaden our customers’ access to the full spectrum of technologies that our scientists have developed.’
Matt Fellows
Related Content

Oxford Genetics gets further £1 million investment boost
Warwickshire-based biotech Mercia Technologies has injected a further £1 million into synthetic biology- specialist Oxford …

Recipharm to open largest Nordic GLP bioanalysis lab
Contract development and manufacturing firm Recipharm has announced plans to invest five million Swedish Krona …

ALS Pharma quadruples Cambridgeshire testing facility in £2m expansion
UK microbiology and chemical analysis company ALS Pharmaceutical has quadrupled the size of its facility …






